One example of this is prevention of proliferation of an SRIF receptor-negative chondrosarcoma by the analogue SMS-201-995 via inhibition of growth hormone, insulin like growth factor-1 (IGF1) and insulin (Reubi, 1985). Here, GH1 is linked to chondrosarcoma.